Freenome (NASDAQ:FRNM) Stock Moved Up to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Freenome (NASDAQ:FRNM) to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

FRNM has been the subject of a number of other reports. Guggenheim started coverage on shares of Freenome in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. Leerink Partners began coverage on shares of Freenome in a research report on Friday, August 14th. They set an “outperform” rating and a $18.00 target price on the stock. BTIG Research started coverage on Freenome in a research note on Monday, August 17th. They issued a “buy” rating and a $17.00 target price on the stock. TD Cowen started coverage on Freenome in a research note on Tuesday, August 18th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Weiss Ratings began coverage on Freenome in a report on Monday, August 24th. They issued a “sell (d+)” rating for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Freenome currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Freenome Price Performance

Shares of FRNM stock opened at $15.99 on Friday. Freenome has a one year low of $9.97 and a one year high of $17.50. The stock has a market capitalization of $1.72 billion, a PE ratio of -266.46 and a beta of 0.48.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. Its approach combines artificial intelligence with multiomics analysis, examining biological signals in blood, including circulating tumor material and other molecular indicators.

The company has focused on noninvasive screening tests for colorectal cancer and other cancers. Freenome’s products remain in development and are being evaluated through clinical research and validation studies; the company’s tests are not described here as broadly approved diagnostic products.

Founded in 2014 and headquartered in the United States, Freenome has worked with healthcare providers, research organizations and pharmaceutical companies to advance its screening technology.